AbbVie to acquire neuroscience drugmaker Cerevel Therapeutics for $8.7 billion
The deal is AbbVie’s latest attempt to expand its drug pipeline as its top-selling treatments, such as Humira, face generic competition.
The deal is AbbVie’s latest attempt to expand its drug pipeline as its top-selling treatments, such as Humira, face generic competition.
